We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GENERIC FIRMS DELAY PAROXETINE LAUNCH DESPITE FDA APPROVAL
GENERIC FIRMS DELAY PAROXETINE LAUNCH DESPITE FDA APPROVAL
March 18, 2004
More than a week after receiving final FDA approval, generic firms Sandoz and Alphapharm have yet to launch their versions of GlaxoSmithKline’s (GSK’s) profitable antidepressant Paxil (paroxetine HCl).